Biotech and Pharma News Roundup: TrumpRx Launches, Roivant's Breakthrough, and More

The biotech and pharma industry has been abuzz with activity this week, with major developments in drug pricing, rare disease treatment, and company personnel. Here's a roundup of the latest news. **TrumpRx Launches Amidst Controversy** President Trump launched TrumpRx, a website aimed at lowering drug prices, on Thursday night. The website, which was touted by Trump and his aides as a platform to reduce prescription drug costs, has been met with skepticism by some in the industry. According to a report by STAT+, TrumpRx is not a new entity, but rather a rebranding of an existing website that allows patients to compare prices for prescription drugs. While the website may provide some transparency in drug pricing, critics argue that it does not address the underlying issues driving high drug costs. **Roivant's Breakthrough in Rare Skin Disease Treatment** In more promising news, Roivant's immune drug significantly outperformed a placebo in clearing lesions caused by a rare skin disease, according to a small trial. The drug, which targets the immune system, showed a significant improvement in patients with the rare skin condition, offering new hope for those affected. This breakthrough is a significant milestone for Roivant, which has been working to develop innovative treatments for rare diseases. **Comings and Goings in the Industry** The biotech and pharma industry has seen a flurry of comings and goings in recent weeks. According to a report by STAT+, there have been several new hires, departures, promotions, and transfers in the industry. While these changes may not always make headlines, they can have a significant impact on the direction and success of companies in the industry. **IPOs, GLP-1s, and Gene Therapy Challenges** The biotech industry has also been grappling with challenges related to IPOs, GLP-1s, and gene therapy. According to a report by STAT+, several biotech companies have struggled with IPOs in recent months, citing regulatory hurdles and market volatility. Meanwhile, companies working on GLP-1s and gene therapy have faced challenges in bringing these innovative treatments to market. **What is a 'Natural' Dye, Anyway?** In other health news, there has been growing interest in "natural" dyes, which are touted as a healthier alternative to synthetic dyes. But what exactly is a "natural" dye? According to a report by Morning Rounds, the term "natural" is often misused in the context of dyes, and can be misleading to consumers. As consumers become increasingly health-conscious, it's essential to understand what we mean by "natural" and to approach such claims with a critical eye. **Hims & Hers Sells Compounded Wegovy Pill** Finally, Hims & Hers, a popular online pharmacy, has begun selling a compounded version of the weight loss pill Wegovy. According to a report by STAT+, the move has raised eyebrows in the industry, as Wegovy is a prescription-only medication that requires careful monitoring by a healthcare professional. While Hims & Hers has assured customers that the compounded pill is safe and effective, some experts have expressed concerns about the risks of selling such a medication online. Overall, it's been a busy week in the biotech and pharma industry, with major developments in drug pricing, rare disease treatment, and company personnel. As the industry continues to evolve, it's essential to stay informed about the latest news and trends.